Skip to content

US · COCP · BIOTECHNOLOGY

Cocrystal Pharma, Inc. (COCP) intrinsic value and stock valuation

$0.95as of 2026-11-21 · Mkt cap 14.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cocrystal Pharma, Inc. DCF and intrinsic value

InvestorsCraft values COCP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from COCP’s statements →

Cocrystal Pharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bothell, WA 98011 cocrystalpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-8.83M
20112025
Free cash flow
-$-8.2M
20112025
Total equity
$6.33M-34.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-9.02M-$-17.88M-$-18.56M-$-38.83M-$-14.22M
Net income-$-8.83M-$-17.5M-$-17.98M-$-38.84M-$-14.19M
EPSd-$-782.11K-$-1.72M-$-1.86M-$-4.77M-$-1.85M
Operating cash flow-$-8.19M-$-16.48M-$-14.67M-$-21.43M-$-12.72M
Capital expenditure-$-10K-$-10K-$-120K-$-70K-$-50K
Free cash flow-$-8.2M-$-16.49M-$-14.78M-$-21.51M-$-12.77M
Total assets$9.71M$13.5M$31.3M$40.8M$79.4M
Total debt$1.5M$1.81M$1.85M$300K$530K
Net debt-$-5.52M-$-8.05M-$-24.5M-$-36.85M-$-58.17M
Total equity$6.33M$9.52M$26.4M$39.6M$77.6M
Cash and short-term investments$7.03M$9.86M$26.4M$37.1M$58.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$5.05M$12.5M$15.2M$12.4M$8.79M
Gross profit-$-5.05M-$-12.54M-$-15.17M-$-12.39M-$-8.79M
Research and development expenses$5.05M$12.5M$15.2M$12.4M$8.79M
Selling, general and administrative expenses$3.96M$5.34M$5.99M$5.75M$5.43M
Other expenses-$-5.05M-$-12.54M-$-17.77M$8.3M-$-8.79M
Operating expenses$3.96M$5.34M$3.39M$26.4M$5.43M
Cost and expenses$9.02M$17.9M$18.6M$38.8M$14.2M
Interest income$130K$540K$640K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$380K$130K$190K$180K$190K
Ebitda-$-8.46M-$-17.38M-$-20.97M-$-17.95M-$-13.99M
Operating income-$-9.02M-$-17.88M-$-18.56M-$-38.83M-$-14.22M
Total other income/expenses, net$190K$370K$570K-$-10K$40K
Income before tax-$-8.83M-$-17.5M-$-17.98M-$-38.84M-$-14.19M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.83M-$-17.5M-$-17.98M-$-38.84M-$-14.19M
Weighted average shares outstanding$11.3M$10.2M$9.65M$8.14M$7.69M
Weighted average diluted shares outstanding$11.3M$10.2M$9.65M$8.14M$7.69M
Balance sheet
20252024202320222021
Cash and short-term investments$7.03M$9.86M$26.4M$37.1M$58.7M
Net receivables$710K$1.22M$890K$720K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.13M$11.6M$29.1M$40.2M$59.3M
Property, plant and equipment, net$1.48M$1.85M$2.12M$620K$930K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$19.1M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.58M$1.88M$2.17M$660K$20.1M
Total assets$9.71M$13.5M$31.3M$40.8M$79.4M
Accounts payable$890K$1.54M$1.22M$610K$580K
Short-term debt$330K$300K$240K$240K$240K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.21M$2.43M$3.26M$1.22M$1.54M
Long-term debt$1.17M$1.5M$1.61M$60K$300K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.17M$1.5M$1.61M$60K$300K
Capital lease obligations$1.5M$1.81M$1.85M$300K$530K
Total liabilities$3.38M$3.93M$4.88M$1.27M$1.84M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-342.25M-$-333.42M-$-315.91M-$-297.93M-$-259.09M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$6.33M$9.52M$26.4M$39.6M$77.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.5M$1.81M$1.85M$300K$530K
Net debt-$-5.52M-$-8.05M-$-24.5M-$-36.85M-$-58.17M
Cash flow statement
20252024202320222021
Net income-$-8.83M-$-17.5M-$-17.98M-$-38.84M-$-14.19M
Depreciation and amortization$70K$130K-$-1.39M$390K$190K
Stock-based compensation$270K$640K$800K$850K$720K
Change in working capital$290K$140K$2.34M-$-2.71M$800K
Accounts receivable$510K-$-330K$0.00-$-720K$560K
Inventory$0.00$0.00$0.00$720K-$-220K
Accounts payable$0.00-$-900K$2.05M-$-320K$220K
Net cash provided by operating activities-$-8.19M-$-16.48M-$-14.67M-$-21.43M-$-12.72M
Investments in property, plant and equipment-$-10K-$-10K-$-120K-$-70K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-10K-$-120K-$-70K-$-50K
Common stock issued$5.37M$0.00$4M$0.00$38.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.37M$0.00$3.99M-$-30K$38.5M
Net change in cash-$-2.83M-$-16.49M-$-10.79M-$-21.54M$25.7M
Cash at end of period$7.1M$9.94M$26.4M$37.2M$58.8M
Operating cash flow-$-8.19M-$-16.48M-$-14.67M-$-21.43M-$-12.72M
Capital expenditure-$-10K-$-10K-$-120K-$-70K-$-50K
Free cash flow-$-8.2M-$-16.49M-$-14.78M-$-21.51M-$-12.77M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cocrystal Pharma, Inc.

        Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

        CEO
        James E. Sapirstein
        Employees
        10
        Beta
        1.41

        Explore

        Frequently asked questions

        What is the intrinsic value of Cocrystal Pharma, Inc. (COCP)?

        InvestorsCraft does not currently publish an intrinsic value for COCP. How the IC value is calculated.

        Is COCP undervalued?

        InvestorsCraft does not publish an undervaluation signal for COCP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.